INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders |
Intellia Therapeutics, Inc. (the Company) held its Annual Meeting
of Stockholders on May18, 2017. The following is a summary of the
matters voted on at that meeting.
| a) |
The stockholders of the Company elected Nessan Bermingham, Ph.D. and Jean-Franois Formela, M.D. as class I directors, each for a three-year term ending at the annual meeting of stockholders to be held in 2020 and until his successor has been duly elected and qualified or until his earlier resignation or removal. The results of the stockholders vote with respect to the election of the class I directors were as follows: |
|
Name |
VotesFor | Votes Withheld | BrokerNon-Votes | |||||||||
|
Nessan Bermingham, Ph.D. |
27,949,155 | 262,647 | 3,606,751 | |||||||||
|
Jean-Franois Formela, M.D. |
27,621,404 | 590,398 | 3,606,751 |
| b) |
The stockholders of the Company ratified the selection of Deloitte Touche LLP as the Companys independent registered public accounting firm for the fiscal year ending December31, 2017. The results of the stockholders vote with respect to such ratification were as follows: |
| For | Against | Abstain | ||
| 31,729,132 | 56,342 | 33,079 |
| c) |
The stockholders of the Company ratified the Companys Amended and Restated 2015 Stock Option and Incentive Plan. The results of the stockholders vote with respect to such ratification were as follows: |
| For | Against | Abstain | BrokerNon-Votes | |||||||||||
| 27,501,943 | 700,154 | 9,705 | 3,606,751 |
About INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA)
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company’s division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company’s subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue. INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA) Recent Trading Information
INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA) closed its last trading session up +0.45 at 14.35 with 177,634 shares trading hands.
